HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed executive vice president while current chief business officer Jon Hunt, PhD, will transition into the role of strategic advisor and consultant, effective March 15, 2023. According to the announcement, these changes are being made ahead of key 2023 milestones, including FDA clearance for the HeartBeam AIMI(TM) system and FDA submission of the HeartBeam AIMIGo(TM) 3D vector ECG first-generation product. The company noted that Hunt will remain involved in the company’s business strategy and outreach, as his expertise and insights from more than three decades of experience in the medical device industry is invaluable. “Jon has made numerous critical contributions to HeartBeam by leading our planning efforts for market introductions of our products,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “We understand his desire for a change of pace and a better work-life-balance, and we are excited that Jon will, as a key consultant, stay close to our strategic discussions and decisions. His dedication and commitment to HeartBeam have been greatly appreciated, and he will be missed in his current role. On behalf of the entire team at HeartBeam, we thank Jon for his outstanding service and leadership, and look forward to his expertise and insights in a consultancy role.”
To view the full press release, visit https://ibn.fm/aNKtp
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment